Sobi presents study data supporting increased possibilities and improved clinical outcomes for people with haemophilia at ISTH
Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July 2019, focusing on the use of Elocta® and Alprolix® in clinical settings such as treatment switches from on demand to prophylaxis and immune tolerance induction (ITI). The reported outcomes include annualised bleeding rates, quality of life as well as joint health. It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented. We will also present data showing the pain and